A fast and convenient new technique to detect the therapeutic target, K-ras mutant, from peripheral blood in non-small cell lung cancer patients

Lung Cancer

Volumn 68, Issue 1, 2010, Pages 51-57

  Tsao, Der An ^b   Yang, Ming Je ^a   Chang, Hui Jen ^b   Yen, Li Chen ^a   Chiu, Hua Hsien ^b   Hsueh, Er Jung ^c   Chen, Yi Fang ^d   Lin, Shiu Ru ^b,e  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b FOOYIN UNIVERSITY   (Taiwan)

^c PINGTUNG CHRISTIAN HOSPITAL   (Taiwan)

^d Gene Target Technology Co Ltd   (Taiwan)

^e FOOYIN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Activating KRAS Detection Chip; Colorimetric membrane array method (CLMA); Epidermal growth factor receptor (EGFR); Non small cell lung cancer; Weighted chemiluminecent membrane array (WCHMA)

Indexed keywords

GENOMIC DNA; K RAS PROTEIN;

ARTICLE; CANCER STAGING; CHEMOLUMINESCENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; GENE ACTIVATION; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SOMATIC MUTATION;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMILUMINESCENT MEASUREMENTS; COLORIMETRY; DISEASE PROGRESSION; GENES, RAS; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS;

EID: 77649186290     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.05.023     Document Type: Article

References (27)

1. McCormick F. ras GTPase activating protein: signal transmitter and signal terminator. Cell 56 (1989) 5-8
2. Shao J., Sheng H., DuBois R.N., and Beauchamp R.D. Oncogenic Ras-mediated cell growth arrest and apoptosis are associated with increased ubiquitin-dependent cyclin D1 degradation. J Biol Chem 275 (2000) 22916-22924
3. Kikuchi A., and Williams L.T. Regulation of interaction of ras p21 with RalGDS and Raf-1 by cyclic AMP-dependent protein kinase. J Biol Chem 271 (1996) 588-594
4. Gohlke H., Kiel C., and Case D.A. Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. J Mol Biol 330 (2003) 891-913
5. Du W., Liu A., and Prendergast G.C. Activation of the PI3'K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res 59 (1999) 4208-4212
6. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., and Velculescu V.E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418 (2002) 934
7. Bos J.L. The ras gene family and human carcinogenesis. Mutat Res 195 (1988) 255-271
8. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res 49 (1989) 4682-4689
9. Wang J.Y., Hsieh J.S., Chang M.Y., Huang T.J., Chen F.M., Cheng T.L., et al. Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg 28 (2004) 721-726
10. Chong I.W., Chang M.Y., Sheu C.C., Wang C.Y., Hwang J.J., Huang M.S., et al. Detection of activated K-ras in non-small cell lung cancer by membrane array: a comparison with direct sequencing. Oncol Rep 18 (2007) 17-24
11. Hsieh J.S., Lin S.R., Chang M.Y., Chen F.M., Lu C.Y., Huang T.J., et al. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance. Am Surg 71 (2005) 336-343
12. Wang J.Y., Hsieh J.S., Lu C.Y., Yu F.J., Wu J.Y., Chen F.M., et al. The differentially mutational spectra of the APC, K-ras, and p53 genes in sporadic colorectal cancers from Taiwanese patients. Hepatogastroenterology 54 (2007) 2259-2265
13. Wang J.Y., Lian S.T., Chen Y.F., Yang Y.C., Chen L.T., Lee K.T., et al. Unique K-ras mutational pattern in pancreatic adenocarcinoma from Taiwanese patients. Cancer Lett 180 (2002) 153-158
14. Lin S.R., Tsai J.H., Yang Y.C., and Lee S.C. Mutations of K-ras oncogene in human adrenal tumours in Taiwan. Br J Cancer 77 (1998) 1060-1065
15. Linardou H., Dahabreh I.J., Kanaloupiti D., Siannis F., Bafaloukos D., Kosmidis P., et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9 (2008) 962-972
16. Perez-Soler R. Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer. Clin Cancer Res 13 (2007) s4589-4592
17. Sequist L.V., Bell D.W., Lynch T.J., and Haber D.A. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25 (2007) 587-595
18. Sun S., Schiller J.H., Spinola M., and Minna J.D. New molecularly targeted therapies for lung cancer. J Clin Invest 117 (2007) 2740-2750
19. Chen Y.F., Wang J.Y., Wu C.H., Chen F.M., Cheng T.L., and Lin S.R. Detection of circulating cancer cells with K-ras oncogene using membrane array. Cancer Lett 229 (2005) 115-122
20. Sambrook J.F.E., and Maniatis T. Molecular cloning: a laboratory manual (1989), Cold Spring Harbor Laboratories Press
21. Maheswaran S., Sequist L.V., Nagrath S., Ulkus L., and Haber D.A. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359 (2008) 366-377
22. Wang J.Y., Lin S.R., Wu D.C., Lu C.Y., Yu F.J., Hsieh J.S., et al. Multiple molecular markers as predictors of colorectal cancer in patients with normal perioperative serum carcinoembryonic antigen levels. Clin Cancer Res 15 (2007) 2406-2413
23. Sheu C.C., Yu Y.P., Tsai J.R., Chang M.Y., Lin S.R., Hwang J.J., et al. Development of a membrane array-based multimarker assay for detection of circulating cancer cells in patients with non-small cell lung cancer. Int J Cancer 15 (2006) 1419-1426
24. Wang J.Y., Hsieh J.S., Chen F.M., Yeh C.S., Alexandersen K., Huang T.J., et al. High frequency of activated K-ras codon 15 mutant in colorectal carcinomas from Taiwanese patients. Int J Cancer 107 (2003) 387-393
25. Guerrero S., Casanova I., Farre L., Mazo A., Capella G., and Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 60 (2000) 6750-6756
26. Giaccone G. The role of gefitinib in lung cancer treatment. Clin Cancer Res 10 (2004) 4233s-4237s
27. Giaccone G. Clinical impact of novel treatment strategies. Oncogene 21 (2002) 6970-6981